StemCell Institute

StemCell Institute Financial Leverage

The Financial Leverage (Equity Multiplier) of StemCell Institute (7096.T) as of Oct 27, 2026 is 3.03. In the previous year, Financial Leverage (Equity Multiplier) was 2.86 — a change of 5.91% (higher).

Financial Leverage

3.03

YoY

5.91%

Last updated:

Financial Leverage (Equity Multiplier) of StemCell Institute is 2026 3.03 . Financial Leverage (Equity Multiplier) of StemCell Institute was 2025 2.86 . It decreases by 5.91% higher compared to the previous year.

The StemCell Institute Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
2.86 JPY
Jan 1, 2020
2.83 JPY
Jan 1, 2021
2.99 JPY
Jan 1, 2022
2.49 JPY
Jan 1, 2023
2.53 JPY
Jan 1, 2024
2.45 JPY
Jan 1, 2025
2.86 JPY
Jan 1, 2026
3.03 JPY
The StemCell Institute Financial Leverage history
YEARFinancial LeverageYoY
3.03+5.91%
2.86+16.83%
2.45-3.39%
2.53+1.95%
2.49-16.97%
2.99+5.81%
2.83-1.20%
2.86+2.37%
2.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemCell Institute Stock analysis

What does StemCell Institute do? StemCell Institute KK operates a cell bank business segment focused on storing umbilical cord blood and cord tissue. The company collects umbilical cord blood from pregnant women through contracts with domestic cooperative hospitals, including university hospitals and obstetric clinics, then processes and stores the stem cells at its centers in Minato-ku, Tokyo, and Midori-ku, Yokohama. The firm generates revenue by charging customers for the separation, storage, and long-term preservation of stem cells, targeting expectant parents seeking future medical options. Its primary customer segment consists of pregnant women who sign storage contracts before childbirth. The company develops regenerative medicine products and new treatment methods, expanding its offerings beyond basic storage. It also invests in childbirth and childcare-related business areas, aligning with its core cell bank operations. StemCell Institute KK's revenue streams include fees for umbilical cord blood banking services and potential future sales of regenerative medicine products developed through its research and development efforts. StemCell Institute KK's business model centers on long-term storage contracts with customers, leveraging its cell processing and storage infrastructure. The firm's revenue is derived from upfront and recurring fees associated with the collection, processing, and preservation of stem cells from umbilical cord blood, with no mention of additional revenue sources such as partnerships or external investments in the provided description. StemCell Institute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemCell Institute stock

Financial Leverage (Equity Multiplier) of StemCell Institute is 3.03 in 2026.

Financial Leverage (Equity Multiplier) of StemCell Institute changed from 2.86 to 3.03, representing a 5.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) StemCell Institute since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s StemCell Institute with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — StemCell Institute

All Key Metrics — StemCell Institute